Načítá se...
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS–RAF–MEK–MAPK pathway, specifica...
Uloženo v:
| Vydáno v: | Cancer Manag Res |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892608/ https://ncbi.nlm.nih.gov/pubmed/29662327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S142269 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|